Climb Bio, Inc.

For the period ended Dec 31, 2025. Filed Mar 5, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 5, 2026

CLYM$11.01+7.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Climb Bio, Inc.
Date: March 5, 2026	By:	/s/ Aoife Brennan
		Aoife Brennan, M.B., Ch.B.
		President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

Alexander Cumbo
Name	Title	Date
/s/ Aoife Brennan	President, Chief Executive Officer and Director	March 5, 2026
Aoife Brennan, M.B., Ch.B.	(Principal Executive Officer)
/s/ Susan Altschuller	Chief Financial Officer	March 5, 2026
Susan Altschuller, Ph.D., MBA	(Principal Financial Officer)
/s/ Cindy J. Driscoll	Senior Vice President, Finance	March 5, 2026
Cindy J. Driscoll, MBA	(Principal Accounting Officer)
/s/ Douglas E. Williams	Director	March 5, 2026
Douglas E. Williams, Ph.D.	(Chairman)
/s/ Alexander Cumbo	Director	March 5, 2026
/s/ Kimberlee C. Drapkin	Director	March 5, 2026
Kimberlee C. Drapkin, CPA
/s/ Judith Dunn	Director	March 5, 2026
Judith Dunn, Ph.D
/s/ Andrew Levin	Director	March 5, 2026
Andrew Levin, M.D., Ph.D.
/s/ Stephen Thomas	Director	March 5, 2026
Stephen Thomas, Ph.D.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.